5/6/2020 6:09:51 AM
Mesoblast Says First Patients Dosed In Phase 2/3 Randomized Controlled Trial Of Remestemcel-l
4/6/2020 6:09:36 AM
Mesoblast Gets FDA Clearance For IND Application To Use Remestemcel-L In Patients With ARDS Caused By COVID-19
4/1/2020 6:03:22 AM
Mesoblast Says FDA Accepted For Priority Review BLA Filing For RYONCIL
3/10/2020 6:07:49 AM
Mesoblast Plans To Evaluate Allogeneic Mesenchymal Stem Cell Product Candidate Remestemcel-L For COVID-19 Lung Disease
2/3/2020 6:06:53 AM
Mesoblast Submits Completed BLA For Ryoncil To US FDA
1/2/2020 6:02:26 AM
Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling BLA For Remestemcel-L
12/17/2019 6:09:42 AM
Mesoblast: Phase 3 Trial Of Revascor Surpasses No. Of Primary Endpoint Events For Trial Completion
8/27/2019 6:13:18 AM
Mesoblast:FDA Provides Guidance On Clinical Pathway To Marketing Application For Revascor
8/12/2019 6:03:29 AM
Mesoblast Appoints Fred Grossman As Chief Medical Officer
6/24/2019 6:27:18 AM
Mesoblast: FDA Grants Rexlemestrocel-L, Orphan Drug Designation For Prevention Of Post-implantation Mucosal Bleeding
6/11/2019 6:04:17 AM
Mesoblast And JCR Pharma Expand Japan License Agreement To Use Of Mesenchymal Stem Cells In Newborns
4/16/2019 6:09:06 AM
FDA Agrees To Rolling Review Of Mesoblast’s BLA For Cell Therapy In Children With SR-aGVHD
3/25/2019 6:04:56 AM
Mesoblast: Licensee Files For Marketing Approval To Treat Epidermolysis Bullosa
1/7/2019 6:05:33 AM
Mesoblast Completes Patient Recruitment In Events-driven Phase 3 Trial Of Revascor
12/19/2018 7:22:59 AM
Mesoblast Appoints Eric Strati To SVP, Commercial
11/11/2018 8:08:35 PM
MESO : Clinically Outcome In NIH Trial Of MPC-150-IM For Heart Failure LVAD Recipients Provides Pathway For Approval